

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**


**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**Fig. 1a**




**Figure 1a:** Liver araCTP levels, when Compound A and Compound B are administered at a dose of 100 mg/kg CE to male NIH Swiss mice by a single i.p. bolus injection at time 0.

## Fig. 1b




**Figure 1b:** Plasma prodrug levels, when Compound A and Compound B are administered at a dose of 100 mg/kg CE to male NIH Swiss mice by a single i.p. bolus injection at time 0.

**Fig. 1c**




**Figure 1c:** Plasma AraC levels, when Compound A and Compound B are administered at a dose of 100 mg/kg CE to male NIH Swiss mice by a single i.p. bolus injection at time 0.

**Fig. 2a**




**Figure 2a:** Liver ara-CTP levels in rat after prodrug administration by continuous i.v. infusion. Time course of liver araCTP levels in two independent studies evaluating activation of Compound A, B or C.

**Fig. 2b**




**Figure 2b:** Dose response of liver araCTP after treatment with Compound A or Compound B.

**Fig. 3a**




**Figure 3a:** Body weight, expressed as a percent of initial weight, as a function of time in mice treated with araC at doses of 30-1000 mg/kg CE for 5 days by daily IP injection. ). The \* indicates  $p < 0.05$  compared with vehicle.

**Fig. 3b**




**Figure 3b:** Body weight, expressed as a percent of initial weight, as a function of time in mice treated with Compound C at doses of 30-1000 mg/kg CE for 5 days by daily IP injection.

Fig. 4a



**Figure 4a:** Hematology endpoints after 5-day treatment with araC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The \* indicates  $p < 0.05$  compared with vehicle. Nucleated bone marrow cells.

**Fig. 4b**



**Figure 4b:** Hematology endpoints after 5-day treatment with aracC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The \* indicates  $p < 0.05$  compared with vehicle. Peripheral blood multinucleated cells (PMN's).

Fig. 4c





Figure 4c: Hematology endpoints after 5-day treatment with araC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The \* indicates  $p<0.05$  compared with vehicle. Peripheral blood mononuclear cells.

Fig. 4d



**Figure 4d:** Hematology endpoints after 5-day treatment with aracC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The \* indicates  $p<0.05$  compared with vehicle. Platelets.